Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for lymphoma are not yet well-characterized and treatment depends on the type of lymphoma, it’s location and stage. Recent developments in the treatment of lymphoma include research into novel chemotherapy regimens, chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates and checkpoint inhibitors, with some therapies alreadyapproved and many being tested in clinical trials.
In 2020, the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2020) was presented as an all-virtual event due to the COVID-19pandemic, however this did not detract from the excellence and quality of data and research presented.
In this roundtable discussion, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, and Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discuss the hottest topics in the treatment of lymphoma presented at ASH 2020.
The post The Lymphoma Sessions: highlights from ASH 2020 appeared first on VJHemOnc.
